These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 2476606)

  • 41. Effects of pimobendan and its metabolite on myofibrillar calcium responsiveness and ATPase activity in the presence of inorganic phosphate.
    van Meel JC; Entzeroth M; Redemann N; Haigh RM
    Arzneimittelforschung; 1995 Feb; 45(2):136-41. PubMed ID: 7710434
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Beneficial Effect of Pimobendan for Severe Heart Failure Due to Transthyretin Cardiac Amyloidosis.
    Okamoto N; Kubo T; Nakashima Y; Ochi Y; Takahashi A; Baba Y; Hirota T; Yamasaki N; Kitaoka H
    Intern Med; 2020 Feb; 59(3):339-343. PubMed ID: 31588087
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Contribution of cAMP-phosphodiesterase inhibition and sensitization of the contractile proteins for calcium to the inotropic effect of pimobendan in the failing human myocardium.
    Böhm M; Morano I; Pieske B; Rüegg JC; Wankerl M; Zimmermann R; Erdmann E
    Circ Res; 1991 Mar; 68(3):689-701. PubMed ID: 1660359
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Renal, but not systemic, hemodynamic effects of dopamine are influenced by the severity of congestive heart failure.
    Ungar A; Fumagalli S; Marini M; Di Serio C; Tarantini F; Boncinelli L; Baldereschi G; Valoti P; La Cava G; Olianti C; Masotti G; Marchionni N
    Crit Care Med; 2004 May; 32(5):1125-9. PubMed ID: 15190961
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effect of pimobendan or benazepril hydrochloride on survival times in dogs with congestive heart failure caused by naturally occurring myxomatous mitral valve disease: the QUEST study.
    Häggström J; Boswood A; O'Grady M; Jöns O; Smith S; Swift S; Borgarelli M; Gavaghan B; Kresken JG; Patteson M; Ablad B; Bussadori CM; Glaus T; Kovacević A; Rapp M; Santilli RA; Tidholm A; Eriksson A; Belanger MC; Deinert M; Little CJ; Kvart C; French A; Rønn-Landbo M; Wess G; Eggertsdottir AV; O'Sullivan ML; Schneider M; Lombard CW; Dukes-McEwan J; Willis R; Louvet A; DiFruscia R
    J Vet Intern Med; 2008; 22(5):1124-35. PubMed ID: 18638016
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinical effect of indolidan in congestive heart failure.
    Corder CN; Puls A; Wilson M
    Int J Clin Pharmacol Ther Toxicol; 1992 Oct; 30(10):405-9. PubMed ID: 1446958
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Single-dose pharmacokinetics and cardiovascular effects of oral pimobendan in healthy cats.
    Yata M; McLachlan AJ; Foster DJ; Hanzlicek AS; Beijerink NJ
    J Vet Cardiol; 2016 Dec; 18(4):310-325. PubMed ID: 27613648
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Acute hemodynamic effects of pimobendan and captopril: a comparative study in the same patients with chronic heart failure].
    Tsuda T; Izumi T; Kodama M; Hanawa H; Ohshima M; Takahashi M; Suzuki M; Aizaki T; Uchiyama H; Shibata A
    J Cardiol; 1992; 22(4):721-9. PubMed ID: 1343639
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Different mechanisms involved in the positive inotropic effects of benzimidazole derivative UD-CG 115 BS (pimobendan) and its demethylated metabolite UD-CG 212 Cl in canine ventricular myocardium.
    Endoh M; Shibasaki T; Satoh H; Norota I; Ishihata A
    J Cardiovasc Pharmacol; 1991 Mar; 17(3):365-75. PubMed ID: 1711596
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cardiovascular profile of UDCG 115 BS-pimobendane and reversibility of catecholamine subsensitivity in severe congestive heart failure secondary to idiopathic dilated cardiomyopathy.
    Baumann G; Ningel K; Permanetter B
    J Cardiovasc Pharmacol; 1989 May; 13(5):730-8. PubMed ID: 2472521
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pimobendan and its use in treating canine congestive heart failure.
    Bowles D; Fry D
    Compend Contin Educ Vet; 2011 Nov; 33(11):E1. PubMed ID: 22101450
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effects of pimobendan on exercise tolerance and quality of life in patients with heart failure.
    Kubo SH
    Cardiology; 1997; 88 Suppl 2():21-7. PubMed ID: 9142432
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Longitudinal analysis of quality of life, clinical, radiographic, echocardiographic, and laboratory variables in dogs with myxomatous mitral valve disease receiving pimobendan or benazepril: the QUEST study.
    Häggström J; Boswood A; O'Grady M; Jöns O; Smith S; Swift S; Borgarelli M; Gavaghan B; Kresken JG; Patteson M; Åblad B; Bussadori CM; Glaus T; Kovačević A; Rapp M; Santilli RA; Tidholm A; Eriksson A; Belanger MC; Deinert M; Little CJ; Kvart C; French A; Rønn-Landbo M; Wess G; Eggertsdottir A; Lynne O'Sullivan M; Schneider M; Lombard CW; Dukes-McEwan J; Willis R; Louvet A; DiFruscia R
    J Vet Intern Med; 2013; 27(6):1441-51. PubMed ID: 24010489
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effect of Pimobendan in Dogs with Preclinical Myxomatous Mitral Valve Disease and Cardiomegaly: The EPIC Study-A Randomized Clinical Trial.
    Boswood A; Häggström J; Gordon SG; Wess G; Stepien RL; Oyama MA; Keene BW; Bonagura J; MacDonald KA; Patteson M; Smith S; Fox PR; Sanderson K; Woolley R; Szatmári V; Menaut P; Church WM; O'Sullivan ML; Jaudon JP; Kresken JG; Rush J; Barrett KA; Rosenthal SL; Saunders AB; Ljungvall I; Deinert M; Bomassi E; Estrada AH; Fernandez Del Palacio MJ; Moise NS; Abbott JA; Fujii Y; Spier A; Luethy MW; Santilli RA; Uechi M; Tidholm A; Watson P
    J Vet Intern Med; 2016 Nov; 30(6):1765-1779. PubMed ID: 27678080
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinical effects of long-term administration of pimobendan in patients with moderate congestive heart failure.
    Sasayama S; Asanoi H; Kihara Y; Yokawa S; Terada Y; Yoshida S; Ejiri M; Horikoshi I
    Heart Vessels; 1994; 9(3):113-20. PubMed ID: 8056717
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pharmacokinetics of oral pimobendan in healthy cats.
    Hanzlicek AS; Gehring R; Kukanich B; Kukanich KS; Borgarelli M; Smee N; Olson EE; Margiocco M
    J Vet Cardiol; 2012 Dec; 14(4):489-96. PubMed ID: 23116650
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effects of the benzimidazole derivatives pimobendan and 2-(4-hydroxy-phenyl)-5-(5-methyl-3-oxo-4,5-dihydro-2H-6- pyridazinyl) benzimidazole . HCl on phosphodiesterase activity and force of contraction in guinea-pig hearts.
    Berger C; Meyer W; Scholz H; Starbatty J
    Arzneimittelforschung; 1985; 35(11):1668-73. PubMed ID: 2418846
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cardiac electrophysiologic and hemodynamic activity of pimobendan (UD-CG 115 BS), a new inotropic agent.
    Kitzen JM; Lynch JJ; Driscoll EM; Lucchesi BR
    J Pharmacol Exp Ther; 1988 Mar; 244(3):929-39. PubMed ID: 3252039
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Sustained hemodynamic and clinical effects of a new cardiotonic agent, WIN 47203, in patients with severe congestive heart failure.
    Maskin CS; Sinoway L; Chadwick B; Sonnenblick EH; Le Jemtel TH
    Circulation; 1983 May; 67(5):1065-70. PubMed ID: 6831672
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Persistent hemodynamic effects without long-term clinical benefits in response to oral piroximone (MDL 19,205) in patients with congestive heart failure.
    Petein M; Levine TB; Cohn JN
    Circulation; 1986 Mar; 73(3 Pt 2):III230-6. PubMed ID: 3510778
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.